New Development in the Concordat Process of İzmir-Based Health Companies
The court lifted the definitive grace period decision for health companies experiencing a financial bottleneck and approved the bankruptcy of an affiliated pharmaceutical company.
New judicial decisions have been issued regarding Türklab Tıbbı Malzemeler and its affiliated companies, which have been in the concordat process due to financial difficulties. The court terminated the definitive grace period decision and ruled for the bankruptcy of one company.
Critical Decision in the Concordat Process
The legal process has evolved into a new stage for Türklab Tıbbı Malzemeler, which entered the sector with the production of pregnancy tests in Turkey and grew through its exports during the pandemic period, along with its affiliated companies. Important rulings were issued by the court regarding the companies that entered a financial bottleneck and declared concordat last year.
The Court Lifts the Measures
The 2nd Commercial Court of First Instance in İzmir reviewed the previously made decisions for the companies carrying out production activities in the İTOB Organized Industrial Zone in the Menderes district. The concordat definitive grace period decision and court measures issued in 2025 for Türklab Tıbbı Malzemeler, owned in partnership by Şahin Yağlıdere and Kartal Yağlıdere, as well as S.K. Teknoloji Araştırma Geliştirme and Farlab İlaç, were lifted.
Bankruptcy Decision for Farlab İlaç
In the continuation of the legal process, the bankruptcy of Farlab İlaç Özel Sağlık Hizmetleri Ticaret Anonim Şirketi, one of the subsidiaries, was decided. It became official that the bankruptcy decision was initiated on October 7.